Agenda

11:30 am – 12:30 pm	General Registration Check-in & Networking Lunch
	Hosted By:
12:30 – 12:45 pm	Welcome & Retinal Innovation Highlights
	Emmett T. Cunningham Jr., MD, PhD, MPH, Partner – Clarus
12:45 – 1:45 pm	Retina Company Showcase
	Moderated By: Tracy Saxton, PhD, Investment Director – Roche Venture Fund Company Presentations: 12:45 – 12:51 \| Alimera Sciences \| Dan Myers, CEO 12:51 – 12:57 \| Catalyst Biosciences \| Edwin Madison, PhD, Chief Scientific Officer 12:57 – 1:03 \| Aerie Pharmaceuticals \| Casey Kopczynski, Chief Scientific Officer 1:03 – 1:09 \| Ocular Therapeutix \| Jonathan Talamo, MD, Chief Medical Officer 1:09 – 1:15 \| Graybug Vision \| Jeffrey Cleland, President & CEO 1:15 – 1:21 \| Apellis Pharmaceuticals \| Cedric Francois, CEO 1:21 – 1:27 \| Translatum Medicus inc (TMi) \| Shelley Boyd, MD, President & CSO 1:27 – 1:33 \| Bioptigen \| Eric Buckland, CEO 1:33 – 1:39 \| TrueVision Systems \| Forrest Fleming, CEO 1:39 – 1:45 \| Bausch + Lomb \| Calvin Roberts, MD, SVP & Chief Medical Officer
1:45 – 2:15 pm	Networking Break
2:15 pm	Financing Environment
	Introduced By: Gilbert H. Kliman, MD, Managing Director – InterWest Partners
2:15 – 2:22 pm	Trends in Private Company Financing & Exits in Ophthalmology
	Jonathan Norris, Managing Director – Silicon Valley Bank
2:22 – 2:30 pm	Public Market Trends in Ophthalmology
	Andrew Gitkin, Head, West Coast Investment Banking – Piper Jaffray
2:30 – 3:00 pm	Innovation in Retinal Imaging: Opportunities & Challenges
	Presentations Introduced by: William J. Link, PhD, Managing Director – Versant Ventures Presenters: History of OCT-A \| David Huang, MD, PhD History of Intraoperative OCT \| Cynthia Toth, MD Panel Discussion Moderated By: William J. Link, PhD, Managing Director – Versant Ventures Participants: Ryan Bouchard, Director, Medical Devices – Ora Heinrich Dreyer, PhD, VP, Medical Division – Leica Microsystems Ralf Kuschnereit, PhD, SVP Ophthalmic Systems Division – Carl Zeiss Meditec AG Kester Nahen, PhD, Managing Director – Heidelberg Engineering
3:00 – 3:30 pm	Paying for Breakthrough Eye Therapies (Biologics, Biosimilars & Gene Therapies)
	Company Presentations Moderated By: Tarek Hassan, MD Presenters: Pfenex \| Hubert Chen, Chief Medical Officer AGTC \| Stephen Potter, Chief Business Officer Panel Discussion Co-Moderated By: Tarek Hassan, MD Gilbert H. Kliman, MD, Managing Director – InterWest Partners Participants: Jay Duker, MD Joshua Schimmer, Senior Research Analyst – Piper Jaffray John Thompson, MD Trex Topping, MD
3:30 – 3:50 pm	Networking Break
3:50 – 4:30 pm	Emerging Approaches to Combination Therapies in AMD & DME
	Company Presentations Moderated By: Mark Humayun, MD Presenters: Regeneron \| David Boyer, MD Aerpio Therapeutics \| Joseph Gardner, President & CEO Allegro Ophthalmics \| Vicken Karageozian, MD, President & CMO Opthea \| Megan Baldwin, PhD, CEO & Managing Director Panel Discussion: Co-Moderated By: Emmett T. Cunningham Jr., MD, PhD, MPH, Partner – Clarus Mark Humayun, MD Participants: Mark Blumenkranz, MD Adnan Butt, Biotech Analyst – RBC Capital Markets Donald D’Amico, MD Pravin Dugel, MD Peter Kaiser, MD
4:30 – 5:10 pm	Masters of the Industry
	Moderated By: Jim Mazzo, Global President of Ophthalmology – Carl Zeiss Meditec Participants: Tony Adamis, MD, Global Head, I2O & Metabolism, Clinical Science – Genentech Frederic Guerard, Worldwide Business Franchise Head, Ophthalmology – Alcon William J. Link, PhD, Managing Director – Versant Ventures Ludwin Monz, PhD, President & CEO – Carl Zeiss Meditec AG
5:10 – 5:15 pm	Closing Remarks
	Gilbert H. Kliman, MD, Managing Director – InterWest Partners
5:15 – 6:15 pm	Networking Reception
	Hosted By: